A
Aktis Oncology, Inc.
AKTS · NASDAQ · Healthcare · 1.3B
Closing price
$18.15
+2.31% · last session
Graham & Buffett's criteria
published figures · last financial year
Price / earningsP/E
—
Price / net assetsP/B
—
Enterprise value / EBITDAEV/EBITDA
-18.7×
Free cash flow yieldFCF yield
-6.3%
Return on equityROE
43.6%
Operating margin
-1149.5%
Net debt / EBITDAbalance-sheet strength
0.4×
Interest coverage
—
How we read it
an educational summary · not advice
Figures provided for information and education — they do not constitute personalized investment advice. Investing carries a risk of capital loss.